Empowering living medicines.
Encellin is focused on advancing next generation therapies, starting with endocrine disorders.
The cell is the original smart machine. All drugs, devices, digital health, and even AI approaches are trying to mirror cellular functions.
Encellin has developed an Encapsulated Cell Replacement Therapy (ENCRT), that helps these cells survive in the body. Encellin’s ENCRT allows enclosed cells to function like smart molecular factories, releasing therapeutics when needed.
THE PROBLEM
Cells play complex roles to ensure our health and safety. When cells are missing, damaged or diseased, the body cannot function correctly.
OUR SOLUTION
A new category of medicine, with early clinical data.
Cells play complex roles to ensure our health and safety. When cells are missing, damaged or diseased the body cannot function correctly. Living medicine are infinitely programmable. ENCRT (Encapsulated Cell Replacement Therapy), is a modular system: any therapeutic cell type can be loaded into it, protected, and enabled to function as a living drug factory inside the body.
Starting with: Endocrine Disorders
In June 2026, Encellin reported early human evidence that transplanted islets can engraft and survive without fibrosis, inside ENCRT, the platform that makes it possible.
